Header Logo

Connection

MILIND JAVLE to MAP Kinase Kinase 2

Back to Details
This is a "connection" page, showing publications MILIND JAVLE has written about MAP Kinase Kinase 2.
MILIND JAVLE
Connection Strength
0.148
MAP Kinase Kinase 2
  1. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28; 116(5):575-583.
    View in: PubMed
    Score: 0.148
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.